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Background: Despite a lack of consensus regarding effectiveness, androgen deprivation therapy (ADT) is a
common treatment for non-metastatic, low-risk prostate cancer. To examine a particular clinical concern regarding
the possible impact of ADT on cognition, the current study combined neuropsychological testing with functional
magnetic resonance imaging (fMRI) to assess both brain activation during cognitive performance as well as the
integrity of brain connectivity.
Methods: In a prospective observational cohort analysis of men with non-metastatic prostate cancer at a Veterans
Affairs medical center, patients receiving ADT were compared with patients not receiving ADT at baseline and at
6 months. Assessments included fMRI, the N-back task (for working memory), the stop-signal task (for cognitive
control), and a quality of life questionnaire.
Results: Among 36 patients enrolled (18 in each group), 30 completed study evaluations (15 in each group); 5
withdrew participation and 1 died. Results for the N-back task, stop-signal task, and quality of life were similar at
6 months vs. baseline in each group. In contrast, statistically significant associations were found between ADT use
(vs. non use) and decreased medial prefrontal cortical activation during cognitive control, as well as decreased
connectivity between the medial prefrontal cortex and other regions involved with cognitive control.
Conclusions: Although ADT for 6 months did not affect selected tests of cognitive function, brain activations
during cognitive control and functional brain connectivity were impaired on fMRI. The long-term clinical
implications of these changes are not known and warrant future study.
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Prostate cancer is the most common non-skin cancer in
American men, and almost half of patients with this dis-
ease receive androgen deprivation therapy (ADT) over
the course of their disease [1,2]. Evidence suggests that
ADT can cause fatigue, decreased sexual function,
gynecomastia, osteoporosis, and metabolic changes [3],
but the adverse effects of ADT on cognition remain un-
clear. Observational and randomized studies have* Correspondence: herta.chao@yale.edu
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reproduction in any medium, provided the orexamined a possible association between androgens and
cognitive function, including a potentially protective ef-
fect of testosterone against age-related cognitive decline
[3-8]. A review [9] of prior studies using traditional
neuropsychological testing in patients with prostate can-
cer treated with ADT showed equivocal findings; results
were interpreted as showing either no effect [10],
impaired function [11-13], or a mixed effect of ADT
(with patients improving on some tests but doing worse
on others) [14].
Functional magnetic resonance imaging (fMRI) pro-
vides a non-invasive method to assess brain activations
during cognitive performance as well as the integrity of
regional functional connectivities at rest. Clinicians havetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cesses are impaired in patients with a medical (e.g., con-
genital heart disease [15]) or neurological condition
(e.g., cerebral palsy [16]). Studies using fMRI have
demonstrated etiology-specific changes in regional brain
activations in patients with neurological or psychiatric
conditions, even when they did not score differently
from control individuals in neurocognitive tasks [17-19].
Thus, fMRI provides a more sensitive measure of brain
functioning than neurocognitive testing alone.
Investigators have used fMRI and other imaging meth-
ods to evaluate the effects of chemotherapy and hormo-
nal therapy on brain function in women with breast
cancer [20]. For example, altered cortical and subcortical
metabolism was found in breast cancer survivors 5-
10 years after receiving adjuvant chemotherapy [21], and
a patient who was diagnosed with breast cancer and
underwent chemotherapy showed more white matter
hyperintensities and altered spatial extents of brain acti-
vation than her non-affected, monozygotic twin, despite
only small differences in working memory performance
[22]. In addition, women with breast cancer taking tam-
oxifen showed widespread cortical hypometabolism on
PET and MRI, when compared with scans in women not
taking tamoxifen [23]. A longitudinal study in pre-
menopausal women with early-stage breast cancer
demonstrated changes in cognitive functioning and cere-
bral white matter integrity after chemotherapy [24]. An-
other recent study demonstrated significantly reduced
activation in the left middle dorsolateral prefrontal cor-
tex and premotor cortex in women with breast cancer
compared with healthy controls irrespective of treatment
history [25].
Our objective was to evaluate the impact of ADT on
cognition using fMRI to study brain activations during a
cognitive task and at rest, the stop-signal-task to study
cognitive control, and the N-back test to study working
memory. As a secondary outcome, we also evaluated
quality of life.
Methods
Participants and baseline clinical assessments
First, patients with non-metastatic prostate cancer at the
VA Connecticut Healthcare System from 01/2009
through 12/2010 were identified. All men who were pre-
scribed ADT—either as adjuvant treatment or because
of biochemical recurrence—were approached for partici-
pation. As per clinical practice, ADT consisted of med-
ical castration with Goserelin 10.8 mg subcutaneously
every 90 days for 6 months, after a lead-in period with
Bicalutamide 50 mg daily. Patients with non-metastatic
prostate cancer who had never been treated with ADT
were evaluated as potential controls, with matching
based on age and level of education. Exclusion criteriawere: active second malignancy; Eastern Cooperative
Oncology Group Performance Status >1; any significant
cardiovascular conditions (e.g., unstable angina, pace-
maker); hepatic, renal, or neurological disease; any inves-
tigational agents; or a score of less than 27 out of 30 on
the mini-mental state examination (MMSE) [26].
Patients who had a history of axis-I psychiatric or sub-
stance (excluding nicotine) use disorders [27] were also
excluded. All participants underwent a health question-
naire interview to ensure eligibility for fMRI. Partici-
pants who had had a prostatectomy were at least
3 months from their surgery and had fully recovered be-
fore study entry. Participants who were to receive radi-
ation to the prostate underwent baseline assessment
before starting any treatment and were also evaluated 3
to 4 months after completion of radiation treatment.
Our study was approved by the Yale Human Investiga-
tion Committee and the Human Investigation Subcom-
mittee of the Veterans Affairs (VA) Connecticut Health
Care System.
Assessments
The ADT-treated participants were studied prior to initi-
ation of ADT and again after 6 months of ADT, with ef-
fective castration documented by measuring testosterone
level. Each individual assessment (questionnaire, per-
formance-based, or radiological), as well as the combin-
ation of assessments (consisting of cognitive testing
during a fMRI scan), are described below.
Quality of life
As a general assessment of overall status, participants
completed standardized Quality-of-Life-Questionnaires
(QOL) for prostate cancer patients (Fact-P©) at baseline
and again at 6 months [28].
N-back (working memory) task
Working memory is a form of short-term memory that
allows individuals to retain and manipulate information
concurrent with engaging in complex tasks such as com-
prehension, reasoning, and learning. A behavioral para-
digm widely used to study working memory is the N-back
task [29,30]. In response to a series of letters displayed at
a rate of 1 every 2 seconds, a higher accuracy rate and
shorter reaction (RT) of correct trials represents better
working memory. Our participants performed an N-back
working memory task outside the MRI scanner at base-
line and also at 6 months.
Stop signal (cognitive control) task
The stop signal task has been validated as a method to
study cognitive control [31,32]. The stop signal task has
two different stimuli randomly mixed in presentation
and time intervals: a “Go” stimulus that instructs
Table 1 Patient characteristics and Quality of life rating
Group ADT n=15 Control n = 15
Age 69.0 ± 5.3 y 66.1 ± 6.2 y
Education 9th grade: 1 9th grade: 1
High School/GED: 5 High School/GED: 5
College 1-3 years: 3 College 1-3 years: 3
College graduate: 2 College graduate: 3
Post-graduate: 4 Post-graduate: 3
MMSE 29.0 ± 1.3 29.5 ± 0.6
Cancer staging Stage II: 13 Stage I: 1
Stage III: 2 Stage II: 12
Stage III: 2
Local therapy Radiation 100% Radiation 26.7%
Surgery 66.7%
Surgery + Radiation 6.7%
QOL at baseline 115± 22 132 ± 18
QOL of life at 6 months 110± 23 128 ± 21
Testosterone at
6 months
0.14 ± 0.10 ng/ml 2.84 ± 0.94 ng/ml
Note: ADT: Androgen Deprivation Therapy; GED: General Education
Development Test; MMSE: Mini Mental State Examination; QOL: FACT-P quality
of life score; there is no difference between groups in age (t = 1.172, p = 0.588,
two-sided two-sample t test); there is no difference between groups in MMSE
score (t = 1.417, p = 0.167, two-sided two-sample t test); staging follows the
current guidelines of the 2010 American Joint Committee on Cancer (AJCC)
that include Gleason score in the staging; there is also no difference across the
two time points in the change of QOL between groups (F = 0.056, p = 0.814,
interaction, repeated measures analysis of variance).
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“Stop” stimulus that instructs participants to withhold
their response. Pressing a button prematurely, prior to
the appearance of the “Go” stimulus, terminates a trial.
Likewise, a trial terminates at button press or when
1 second has elapsed after the appearance of the stop
signal. A greater accuracy rate of “Go” and “Stop” trials
indicates better cognitive control. Furthermore, in the
stop signal task, participants can slow down in their Go
trial response after they encounter a Stop error. This
phenomenon, termed “post-error slowing”, is a useful
index of how well participants are monitoring their own
performance. Both inhibitory control and performance
monitoring are critical to cognitive control. Our partici-
pants performed the SST during fMRI, both at baseline
and at 6 months.
Imaging protocol
Participants underwent fMRI during a resting state and
while performing the stop signal task (as noted above).
Functional blood oxygen level dependent (BOLD) signals
were acquired using a 3 T scanner. Details of the im-
aging protocol and statistical modeling of brain images
during stop signal task and at rest were as described pre-
viously [33]. Briefly, functional regions of interest were
defined based on activated clusters from whole brain
analysis. One of the main activated clusters was the
medial prefrontal cortex (MPFC) which, as demon-
strated in earlier work, plays a critical role in cognitive
control [34,35].
Statistical analysis
We estimated the sample size required to observe a
group-by-time interaction effect on the basis of a previ-
ous pharmacological fMRI study [36]. The MPFC
showed an effect size of 0.414 for the identical contrast
in the stop signal task, according to Cohen’s f-hat =
square root of [(Df/N)*(F-1)] [37]. The standard devia-
tions for the interaction and within-cell error were 0.83
and 1.12, respectively. Using these results, and for a
Type I error rate = 0.05 as well as assuming a balanced
design, a sample size of 16 in each cell will have a power
of 85% to detect group by time interaction. In a region
of interest analysis, we derived the effect size (extent) of
MPFC activation of stop > go trials [38]. Analyses were
done based on the signals acquired; thus, “blinding” of
results according to treatment group was not relevant. A
significant effect of ADT would manifest as differences
in regional brain activations for the contrast “(follow-up
minus baseline in controls) > (follow-up minus baseline
among patients receiving ADT)”. Signals obtained by
fMRI from a task during rest can provide valuable infor-
mation about the integrity of brain function, reflecting
the intrinsic functional organization of the brain [39,40].We analyzed the resting state BOLD signals with the
MPFC as the region of interest.
For further details on N-back working memory task,
stop signal task, imaging protocol and imaging data ana-
lysis during stop signal task and resting state please see
Additional file 1.Results
From 01/2009 to 1/2011, 18 patients with non-
metastatic prostate cancer receiving ADT and 18 control
patients not receiving ADT were enrolled. One man died
of a cause unrelated to prostate cancer and five with-
drew their participation, resulting in 15 study partici-
pants undergoing ADT and 15 control participants
(Table 1). These 30 study participants completed all
scheduled assessments.Quality of life scores
No statistically significant differences between ADT
patients and control patients were found in QOL scores
at baseline, or with regard to change over 6 months
using the FACT-P© questionnaire (Table 1). Of note,
FACT-P© does not specifically assess cognitive function.
Table 3 Behavioral performance in the stop signal task
SSRT (ms) Median go
RT (ms)
%go %stop PES (effect size)
ADT_B 267 ± 71 697± 127 90.9 ± 5.5 56.5 ± 6.0 0.83 ± 1.72
ADT_F 278 ± 37 678± 123 89.6 ± 5.2 53.1 ± 3.7 1.21 ± 1.12
Control_B 260 ± 57 676± 122 91.6 ± 5.9 56.5 ± 4.5 1.73 ± 1.56
Control_F 268 ± 56 705± 115 91.2 ± 5.4 56.9 ± 5.8 1.49 ± 1.35
P value* 0.480 0.243 0.567 0.051 0.310
Note: B: baseline; F: follow-up; SSRT: stop-signal reaction time; go RT: reaction
time of correct go trials; %go and %stop: percentage of successful go and
stop trials; PES: post-error slowing; all values are mean± standard deviation; *P
value of the group by time interaction in repeated measures analysis of
variance
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task
As measured by the N-back task or by the stop-signal-
task, no statistically significant differences in cognitive
performance were observed at 6 months compared to
baseline in either group (Tables 2 and 3).
Table 2 shows the results of N-back task performance
scores. Overall, correct response rate decreased with in-
creasing memory load for both control and ADT partici-
pants. Three-way repeated measures ANOVA with time
(baseline vs. follow-up) and load (0-, 1-, and 2- back) as
within-subject variables, and group (control vs. ADT) as
the between-subject variable, showed that the interaction
was not significant for hit rate (p = 0.989) or reaction
time (RT) (p = 0.948) within the correct trials. Three-way
repeated measures ANOVA with time (baseline vs. fol-
low-up) and load (0- vs. 1- back, or 0- vs. 2-back) as
within-subject variables, and group (control vs. ADT) as
the between-subject variable, also showed that none of
the interactions were significant (p = 0.859 and p = 0.934,
respectively, for 0- vs. 1- back and 0- vs. 2- back re: hit
rate; p = 0.814 and p = 0.732, respectively, for 0- vs. 1-
back and 0- vs. 2- back re: RT of correct trials). We con-
ducted two-way repeated measures ANOVA separately
for 0-, 1-, and 2- back data, which again yielded non-
significant interactions (Table 2). These results indicated
indistinguishable N-back task performance between the
two groups across the two time points.
Table 3 shows the performance outcomes of the stop
signal task for the ADT and control group, at baseline
and at 6 months. We recorded the Go success rate, Stop
success rate, reaction time (RT) of Go success trials, the
stop signal reaction time (SSRT), as well as the effect
size of post-error slowing (i.e., how much participants
slowed down in a Go trial following a Stop error), as an
index of performance monitoring. The results showed
that there were no differences in performance at
6 months compared to baseline in either group.
Brain activations during cognitive control using the
stop-signal-task
Brain activations while performing the stop-signal-task
were similar between baseline and follow-up for the con-
trol group. In contrast, regional brain activations wereTable 2 Performance in the N-back working memory task
0-back (correct %) 0-back (RT, ms) 1-back (correc
ADT_B 98± 3 545 ± 114 85 ± 13
ADT_F 97 ± 5 571 ± 91 86 ± 11
Control_B 99 ± 2 491 ± 88 85 ± 14
Control_F 99 ± 1 540 ± 87 89 ± 3
P value* 0.402 0.389 0.577
Note: B: baseline; F: follow-up; RT = reaction time of correct trials; *P value of the grsignificantly diminished in the ADT group at follow-up,
as compared to baseline (Figure 1). These differences
were most prominent in the medial prefrontal cortex
(MPFC), right insula, and right middle/inferior frontal
cortices. As previous work has demonstrated, the pre-
frontal cortex plays a critical role in cognitive control
[34,35]. In a region of interest analysis, we focused on
the MPFC and extracted the effect size of activation for
individual participants. A repeated measures analysis of
variance, with the ADT vs. control as the between-
subject factor and follow-up vs. baseline as the within-
subject factor, showed that ADT significantly decreased
medial prefrontal cortical activation during cognitive
control (F1,28 = 7.903, p = 0.009, group by time inter-
action, Figure 2).
Functional connectivity of medial prefrontal cortex during
a resting state
Despite performance scores on N-back task and stop-
signal-task that were similar to the control patients,
ADT patients showed decreased MPFC brain activa-
tions on fMRI at 6 months while performing the stop
signal task. We were interested in whether changes on
fMRI could also be observed when patients were not
performing any cognitive tasks and studied the correl-
ation of low frequency BOLD signals between the
MPFC and other brain regions during a resting state.
This resting state imaging reflects the functional con-
nectivity between different brain regions and measures
how well individual brain regions activate in at %) 1-back (RT, ms) 2-back (correct %) 2-back (RT, ms)
668 ± 147 63 ± 15 746 ± 159
704 ± 165 64 ± 17 787 ± 173
585 ± 157 75 ± 17 677 ± 152
626 ± 139 78 ± 13 714 ± 126
0.932 0.493 0.920





Figure 1 Regional brain activations during cognitive control while performing the stop signal task. ADT=patients who received 6 months of
androgen deprivation therapy; Controls =patients who did not receive any hormonal therapy; B = baseline; F = at 6- month follow-up. The significance
of activation, as reflected by a map of T values (color bar), is shown here on a structural brain image in axial sections, from z= -10 to z=+60, with
adjacent sections 10 mm apart. Neurological orientation: Right (R) = right. Note that ADT patients showed diminished activations in a number of brain
regions at 6 month follow-up, including the medial prefrontal cortex (MPFC), an area critical for cognitive control.
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rity of brain functions.
The results of an analysis of variance showed that,
compared with the control group, ADT patients had





















Figure 2 The effect size of medial prefrontal cortical (MPFC) activations
on the right panel; B =baseline; F = at 6-month follow-up. In each panel, each
bars indicate the mean value of the effect sizes of MPFC activations. Individua
but, on average, the ADT group showed significant decrease in MPFC activati(p < 0.001, uncorrected; Figure 3) with the dorsolateral
prefrontal cortex (DLFPC), right insula, right superior
temporal gyrus, and the rostral anterior cingulate cor-








. Control patients are shown on the left panel; ADT patients are shown
symbol and line represents the data of an individual patient. The gray
ls varied in the change of MPFC activations from baseline to follow-up,
ons after 6 months of ADT, as compared to the control group.
L        R
(b)(a)
(c)
Figure 3 Changes in resting state functional connectivity with the medial prefrontal cortex as result of ADT. After 6 months of ADT,
patients showed decreased connectivity with the dorsolateral prefrontal cortex (DLPFC), rostral anterior cingulate cortex, and the insula, all on the
right side, as compared to control patients. (a) ADT_B>ADT_F; (b) Control_B > Control_F; (c) (Control_F > Control_B) – (ADT_F>ADT_B). B:
baseline; F: follow-up. The significance of difference, as reflected by a map of T values (color bar), is shown here on a structural brain image in
axial sections, from z = -10 to z =+60, with adjacent sections 10 mm apart. Neurological orientation: Right (R) = right.
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Studies of traditional neurocognitive testing without
brain imaging have shown equivocal impact of ADT on
cognitive function. In the current study, we found sup-
pressive effects on brain activations and disruption in
functional connecticity on fMRI in prostate cancer
patients after 6 months of ADT. Interestingly, perform-
ance in neurocognitive testing and their QOL scores
remained similar compared to their baseline, and control
patients without ADT did not show any fMRI changes.
Our patients were matched by age and level of educa-
tion, and all assessments were performed either before
or at least 3 months after any surgery or radiation treat-
ment to minimize any impact of treatment-related
symptoms.
The stability of cognitive performance scores after six
months of ADT is consistent with a recent report [41]
that used neurocognitive tesing alone in a larger sampleof patients receiving twelve months of ADT. In contrast,
the changes we found for brain activations on fMRI
while performing the stop-signal-task after 6 months of
ADT were substantial.
Previous work has demonstrated that the MPFC and a
network of brain regions interacting with the MPFC play
a critical role during cognitive control [34,35]. The find-
ings of altered MPFC activation following ADT are con-
sistent with previous literature on the modulatory effects
of androgen on cerebral cortical activities [42-46]. For
example, a higher level of free testosterone was asso-
ciated with greater cerebral blood flow in the hippocam-
pus and prefrontal cortices in elderly men [45],
testosterone replacement therapy increased cerebral
blood perfusion in the midbrain and prefrontal cortex in
hypogonadal men [42], and administration of testoster-
one increased ventral striatal responses to reward in
healthy women [44]. A preliminary report of decreased
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cessing in five men undergoing ADT [47] is consistent
with our results in suggesting a suppressive effect of
ADT on brain activity.
As mentioned previously, neuroimaging studies have
reported differences in regional brain activations in neuro-
logical or psychiatric patients even when they performed
at a level equal to their demographically-matched control
participants. These performance-independent changes in
brain activities cannot be accounted for by effort or mo-
tivation, and potentially represent the neural correlates
specific to the cerebral pathologies. Similarly, the find-
ings of decreased cortical activations in prostate cancer
patients undergoing ADT, despite similar performance
scores on neurocognitive testing, indicate that changes
in brain activations were not a result of these patients
being less engaged in the task, as compared with their
counterparts. Furthermore, neurocognitive performance
is potentially subject to practice effects whereby partici-
pants’ performance improves upon repeated testing.
Performance-independent differences in brain activa-
tions may thus be more objective and reveal subtle
changes in brain function that cannot be measured by
neurocognitive testing alone.
Limitations of this study include a small sample size
and a limited duration of ADT exposure, yet we were
able to demonstrate an impact of therapy. Although
our study design supports the validity of our results,
the results should be considered preliminary with the
need for replication in future work. Our study is dis-
tinctive in evaluating the effects of ADT using func-
tional imaging; it also is novel in demonstrating a
disruption of functional connectivity at rest in patients
treated with ADT. In addition, although our study was
not a randomized trial, the potential impact of ADT
on brain activation should be detectable using either
randomized or observational approaches. Finally, our
study cannot answer questions such as whether the dif-
ferences observed using fMRI would worsen over time
with or without continued ADT, or whether even these
current effects would eventually lead to clinically ap-
parent signs or symptoms. Future studies with longer
follow-up are warranted to answer these important
questions.Conclusion
ADT limited to 6 months did not affect scores on
selected tests of cognitive function. However, using sen-
sitive techniques involving fMRI, ADT for 6 months
suppressed brain activations during cognitive control
and disrupted brain functional connectivity in prostate
cancer patients. The long-term clinical implications of
these changes are not known and warrant future study.Additional file
Additional file 1: Supplemental material.
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